Original news and analysis on international IP policy
For anyone in Egypt in recent months or years, it was impossible to ignore the extraordinary destitution of masses of people living in dusty, stark cement structures everywhere on the edges of Cairo or the choked roads clogged with a far-too-rapidly swollen population. Reports from the ground via digital technologies chronicled events that hit this week, but it might be the digital silence today that seals the change.
American lawmakers aren’t wasting any time getting down to business after President Obama stressed the importance of spurring innovation during his annual State of the Union address this week and cited the need for the United States to regain its competitive edge, particularly when up against countries such as China and India. A slew of related bills are emerging in Congress.
The Executive Board session of the World Health Organization ended early on Monday after a week of discussions that settled some issues but left some others for the next governing meeting of the organisation in May, with much to do until then. The WHO is facing a significant gap in its budget and a programme of reforms is brewing.
World Health Organization members yesterday struck a compromise allowing a Swiss industry representative to sit on a committee selecting proposals for research and developing financing for neglected diseases, disregarding the fact that he is author of one of the proposals. Special safeguards were added to prevent undue influence, but questions remain for some about a conflict of interest.
World Health Organization members today raised strong concerns that a working group they mandated last May to address problems with WHO policy on counterfeit and substandard medicines has yet to be formed - with four months remaining before it must report back to members.
One delegation called for a halt to WHO activities on anti-counterfeiting until the outcome of the working group is accepted by member states.
A seemingly overworked and impoverished World Health Organization opened its Executive Board session today with calls for reform amid deep concerns about its financial future. Meanwhile, dissension arose over an industry representative named by the WHO secretariat to a new research and development funding working group, sparking the WHO director general to cast doubt on the role of industry in such groups.
Patents will soon receive less protection in the United States. That’s the view of many experts who have been closely following Microsoft Corp. v. i4i Ltd. Partnership, which will be argued before the United States Supreme Court later this year.
Although attempts to repeal last year’s healthcare reform bill and efforts to get the deficit under control may take up much of the United States Congress’ time this year, lawmakers are expected to tackle a number of intellectual property-related priorities lawmakers, including patent reform, internet neutrality, and enforcement during the new 112th session.
In today’s global economy, there is an increasing convergence of intellectual property and finance. Wall Street is grappling with how to recognise the true value of a firm’s intellectual property. Companies are realising that simply accumulating patents does not necessarily increase their firms’ value, but it is how those patents are used that can attract capital. And drug companies facing massive numbers of upcoming patent expiries, a deflated economy and other market pressures, are looking to diversify their portfolios to stay in the black.
The year 2010 was a turbulent year for intellectual property law in the United States, and 2011 promises more of the same. The following are some of the top US IP developments to watch in the coming year.
A top Swiss company executive on pandemic influenza and HIV/AIDS research took the reins of the Geneva-based Medicines for Malaria Venture this week, just weeks after MMV was given international organisation status by the Swiss government.
A decision by the Indian Patent Office to reject a patent on an AIDS drug last week has drawn acclaim from civil society and Indian generic pharmaceutical industries. The decision was not based on a controversial article of Indian law aimed at preventing patent extensions but rather on the grounds of non-inventiveness. Abbott Laboratories, meanwhile, presented Intellectual Property Watch with justification for its Indian patent request.